Loyal has secured an exclusive veterinary license from Crinetics Pharmaceuticals for CRN01941, rebranded as LOY-003.
LOY-003 aims at extending the lifespan of large-breed dogs with projected market availability in 2026.
This partnership leverages the parallel between dog aging research and human therapeutic development, particularly for acromegaly.
The oral administration of LOY-003 offers a cost-effective and convenient treatment in contrast to injectable solutions.
Crinetics co-founder Stephen Betz will join the Loyal Board of Directors, reflecting a shared vision between the companies.

Loyal is a clinical-stage startup focused on creating veterinary drugs aimed at enhancing the longevity and health of dogs. They are at the forefront of developing treatments with the goal of extending the healthy lives of canines. Pet owners can sign up to receive news about product launches and opportunities to involve their dogs in Loyal's clinical studies. The company also provides insights into canine aging and wellness through its team of veterinary experts. With a robust lineup of press releases and announcements, Loyal is actively engaging in community outreach and participation in the pursuit of canine longevity.

Loyal

Developing medicines for dogs to extend life and health.

Loyal Partners with Crinetics Pharmaceuticals

Recent Partnership News